Emergence of clostridium difficile ribotype 027 in Germany: Epidemiological and clinical characteristics;Clostridium-difficile-Ribotyp 027: Epidemiologie und Klinik des erstmaligen endemischen Auftretens in Deutschland

Zeitschrift fur Gastroenterologie

Volumn 48, Issue 9, 2010, Pages 1120-1125

  Jansen, A ^a   Kleinkauf, N ^a   Weiss B ^a   Zaiss, N H ^a   Witte, W ^a   Bornhofen, B ^b   Kist, M ^c   Von Eichel Streiber, C ^d   Neumann, M ^e   Michels, H ^f   Eckmanns, T ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b Landesuntersuchungsamt Rheinland Pfalz   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Germany)

^f Gesundheitsamt der Kreisverwaltung Trier Saarburg   (Germany)

Author keywords

infectious colitis; intestine; pseudomembranous colitis

Indexed keywords

CEFOXITIN; CEFTRIAXONE; CEPHALOSPORIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CYCLOSERINE; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; SULTAMICILLIN;

ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM DIFFICILE RIBOTYPE 027; DEATH CERTIFICATE; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; ENDEMIC DISEASE; ENVIRONMENTAL DISEASE; EPIDEMIC; FATALITY; FECES CULTURE; GERMANY; HOSPITAL ADMISSION; HOSPITAL PERSONNEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PSEUDOMEMBRANOUS COLITIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; RIBOTYPING; RISK FACTOR; TOXIC MEGACOLON;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; RIBOTYPING; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 77956956150     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1245269     Document Type: Article

References (23)

1. Bignardi G E. Risk factors for Clostridium difficile infection. The Journal of Hospital Infection 1998 40 1-15
2. Spencer R C. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. The Journal of Antimicrobial Chemotherapy 1998 41 (Suppl C) 21-27
3. Kim K H., Fekety R, Batts D H. et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. The Journal of Infectious Diseases 1981 143 42-50 (Pubitemid 11152596)
4. Kuijper E J., Berg R J., Debast S van den et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerging Infectious Diseases 2006 12 827-830
5. McDonald L C., Killgore G E., Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. The New England Journal of Medicine 2005 353 2433-2441
6. Smith A. Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Euro Surveill 2005 10 E050630.2
7. Borgmann S, Kist M, Jakobiak T et al. Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany. Euro Surveill 2008 13 (49) 17057
8. Kuijper E J., Coignard B, Brazier J S. et al. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill 2007 12 (6) E1-E2
9. Robert Koch-Institut. Epidemiologisches Bulletin 46 / 2007. www.rki.de
10. Morgan O W., Rodrigues B, Elston T et al. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS ONE 2008 3 e1812
11. Burckhardt F, Friedrich A, Beier D et al. Clostridium difficile surveillance trends, Saxony, Germany. Emerging Infectious Diseases 2008 14 691-692
12. Vonberg R P., Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients, Germany. Emerging Infectious Diseases 2007 13 (1) 179-180
13. Pepin J, Saheb N, Coulombe M A. et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005 41 (9) 1254-1260
14. Biller P, Shank B, Lind L et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007 28 198-201
15. Weiss B, Kleinkauf N, Eckmanns T et al. Risk factors related to a hospital-associated cluster of Clostridium difficile PCR ribotype 027 infections in Germany During 2007. Infect Control Hosp Epidemiol 2009 30 282-284
16. Hall J F., Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg 2008 196 (3) 384-388
17. Koss K, Clark M A., Sanders D S. et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006 8 149-154
18. Seder C W., Villalba M R., Robbins J Jr et al. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg 2009 197 (3) 302-307
19. Prendergast T M., Marini C P., DAngelo A J. et al. Surgical patients with pseudomembranous colitis: factors affecting prognosis. Surgery 1994 116 768-774; discussion 774 775
20. Hedge D D., Strain J D., Heins J R. et al. New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag 2008 4 949-964
21. Aas J, Gessert C E., Bakken J S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003 36 (5) 580-585, Epub 2003 Feb 14
22. Empfehlungen des Robert Koch-Instituts zu Hygienemaßnahmen bei Patienten mit Durchfällen aufgrund von toxinbildendem Clostridium difficile. Erscheinungsdatum (aktualisierte Version)11.12.2008 http://www.rki.de/cln-100/nn-717602/DE/Content/Infekt/Krankenhaushygiene/ Erreger-ausgewaehlt/Clostridium/Tabelle-Uebersicht.html2007
23. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 2009 33 (Suppl 1) S42-S45